FMP

FMP

Enter

IMUX - Immunic, Inc.

Profile of Immunic, Inc.(IMUX), Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral imm

About

ceo

Dr. Daniel Vitt Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.immunic-therapeutics.com

exchange

NASDAQ

Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

CIK

0001280776

ISIN

US4525EP1011

CUSIP

4525EP101

Address

1200 Avenue of the Americas

Phone

332 255 9818

Country

US

Employee

77

IPO Date

Apr 17, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep